More Competition Requires Better DifferentiationWith so many companies developing drugs for the same target antigen and diseases, antibody differentiation is the key to delivering commercial results.While there is a multitude of differentiation approaches that drug developers can adopt, getting a result in a commercial environment is a different matter. There are huge time and cost pressures. And even bigger pressure to deliver results.Antibody Engineering and Discovery 2013 is the annual antibody meeting to focus on developing better, differentiated antibody candidates, tackling the specific needs of drug developers. With a focus on delivering in a commercial environment, this is a meeting that will help you:Adapt, or adopt new, discovery platforms to improve the therapeutic potential of your antibody candidatesEnhance biophysical and functional properties to differentiate your antibody and enhance clinical performanceUnderstand how drug developers are using novel antibody-based formats to meet their clinical and commercial goals Because delivering in a commercial environment is the focus, speakers and delegates are dominated by drug developers who can tell you first-hand how to discover and develop differentiated antibodies. Presenters include heads of antibody programs from Pfizer, Novartis, Merck, AbbVie, MedImmune, Amgen and BMS. Heavyweights of the antibody field, George Georgiou and Ira Pastan, will outline radically different discovery and engineering approaches that will help propel your development efforts forwards. Plus, the FDA  will update you on their evolving regulatory expectations regarding antibody development.Get more details of who is speaking and what’s being covered here.Take Away Useable Information That Will Make a Difference to Your Business So how can you be sure attending this conference becomes the best two days you spend away from the lab this year?This is a very different type of antibody meeting. You’ve said that the quality of discussion and the usability of the knowledge you take away from the meeting is critical. The conference will deliver information that’ll make a tangible difference to your performance when you return. A premium is placed on knowledge sharing and networking. Here’s how:Restricting the number of attendees to 100. This promotes knowledge sharing and makes it possible to meet every speaker and delegate. This is an intimate meeting; you can have in-depth conversations that deliver solutions.The audience is weighted so that at least 70% of attendees are drug developers.